NeuroDerm receives funding for phase 2 clinical trial of Parkinson’s disease drug
Part of the Foundation’s 2013 Therapeutic Pipeline program, the grant will support an upcoming phase 2 clinical trial with the subcutaneously delivered drug that is currently under development.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.